Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension

International Clinical Psychopharmacology

Volumn 29, Issue 3, 2014, Pages 125-137

  Tse, Lurdes ^a,b   Procyshyn, Ric M ^b   Fredrikson, Diane H ^a   Boyda, Heidi N ^a,b   Honer, William G ^a,b   Barr, Alasdair M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BC Mental Health and Addictions Research Institute   (Canada)

Author keywords

antihypertensive agent; antipsychotic agent; hypolipidemic agent; metabolic syndrome

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANOREXIGENIC AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; FLUVOXAMINE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MELATONIN RECEPTOR; METFORMIN; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; RAMELTEON; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TELMISARTAN; TOPIRAMATE; TRIACYLGLYCEROL; VALSARTAN;

ANESTHESIOLOGY; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INFORMATION RETRIEVAL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; AGONISTS; CHEMICALLY INDUCED; DYSLIPIDEMIAS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, MELATONIN; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84897500213     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000014     Document Type: Review

References (68)

1. Alberti KG, Zimmet P, Shaw J (2005). The metabolic syndrome-a new worldwide definition. Lancet 366:1059-1062.
2. Al-Mallah M, Khawaja O, Sinno M, Alzohaili O, Samra A (2010). Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis. Cardiol J 17:448-456.
3. Anderson G, Maes M (2012). Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis 27:1-7.
4. Apotex Inc. (2011). Apo-SimvastatinsPr Product Monograph. Toronto, Canada: Apotex Inc.
5. Assunção SS, Ruschel SI, Rosa Lde C, Campos JA, Alves MJ, Bracco OL, de Lima MS (2006). Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev Bras Psiquiatr 28:270-276.
6. AstraZeneca Canada Inc. (2003). CrestorsPr (Rosuvastatin Calcium) Product Monograph. Canada: AstraZeneca.
7. Bailey C (2005). Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 7:675-691.
8. Baptista T, Kin NNY, Beaulieu S (2004). Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions. Clin Pharmacokinet 43:1-15.
9. Baptista T, Martinez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, et al. (2006). Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 51:192-196.
10. Baptista T, Rangel N, Fernández V, Carrizo E, El Fakih Y, Uzcátegui E, et al. (2007). Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 93 (1-3):99-108.
11. Baptista T, Uzcátegui E, Rangel N, El Fakih Y, Galeazzi T, Beaulieu S, et al. (2008). Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 159 (1-2):250-253.
12. Baymiller SP, Ball P, McMahon RP, Buchanan RW (2003). Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res 59:49-57.
13. Bland JM, Altman DG (2011). Comparisons against baseline within randomised groups are often used and can be highly misleading. Trials 12:264.
14. Borba CP, Fan X, Copeland PM, Paiva A, Freudenreich O, Henderson DC (2011). Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. J Clin Psychopharmacol 31:653-658.
15. Boyda H, Tse L, Procyshyn R,Wong D,Wu T, Pang C, et al. (2010a). A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 34:945-954.
16. Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM (2010b). Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 31:484-497.
17. Boyda H, Procyshyn R, Tse L, Hawkes E, Jin C, Pang C, et al. (2012a). Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatry Neurosci 37:407-415.
18. Boyda H, Procyshyn R, Tse L, Wong D, Pang C, Honer W, et al. (2012b). Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology 62:1391-1400.
19. Boyda H, Procyshyn R, Pang C, Hawkes E,Wong D, Jin C, et al. (2013a). Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine. Plos One 8:e53459.
20. Boyda H, Procyshyn R, Tse L, Xu J, Jin C,Wong D, et al. (2013b). Antipsychotic polypharmacy increases metabolic dysregulation in female rats. Exp Clin Psychopharmacol 21:164-171.
21. Bremner WF, Sothern RB, Kanabrocki EL, Ryan M, McCormick JB, Dawson S, et al. (2000). Relation between circadian patterns in levels of circulating lipoprotein (a), fibrinogen, platelets, and related lipid variables in men. Am Heart J 139:164-173.
22. Byington RP, Worthy J, Craven T, Furberg CD (1990). Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experience. Am J Cardiol 65:1287-1291.
23. Caniato RN, Alvarenga ME, Garcia-Alcaraz MA (2006). Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine. Aust N Z J Psychiatry 40:691-697.
24. Carrizo E, Fernández V, Connell L, Sandia I, Prieto D, Mogollón J, et al. (2009). Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 113:19-26.
25. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773.
26. De Hert M, Kalnicka D, Rv Winkel, Wampers M, Hanssens L, Eyck DV, et al. (2006). Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 67:1889-1896.
27. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2011). Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114-126.
28. Drici M, Priori S (2007). Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiol Drug Saf 16:882-890.
29. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM (2004). Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 192:19-27.
30. Faulkner G, Cohn TA (2006). Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatr 51:502-511.
31. Fogari R, Zoppi A, Pasotti C, Poletti L, Tettamanti F, Malamani G, et al. (1989). Plasma lipids during chronic antihypertensive therapy with different [beta]-blockers. J Cardiovasc Pharmacol 14:S28-S32.
32. Gupta S, Rajaprabhakaran R (1994). Paradoxical hypertension associated with clozapine. Am J Psychiatry 151:148.
33. Hahn MK, Remington G, Bois D, Cohn T (2010). Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. J Clin Psychopharmacol 30:706-710.
34. Hanssens L, De Hert M, Kalnicka D, van Winkel R,Wampers M, Van Eyck D, et al. (2007). Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int Clin Psychopharmacol 22:43-49.
35. Henderson D, Fan X, Copeland P, Borba C, Daley T, Nguyen D, et al. (2007). A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 115:101-105.
36. Honer WG, Procyshyn RM, Chen EY, MacEwan GW, Barr AM (2009). A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy. J Psychiatry Neurosci 34:433-442.
37. Kabinoff GS, Toalson PA, Healey KM, McGuire HC, Hay DP (2003). Metabolic issues with atypical antipsychotics in primary care: dispelling the myths. Prim Care Companion J Clin Psychiatry 5:6-14.
38. Kim S, Lee H, Jung D, Suh C, Park S (2006). Cognitive effects of low-dose topiramate compared with oxcarbazepine in epilepsy patients. J Clin Neurol 2:126-133.
39. Klein D, Cottingham E, Sorter M, Barton B, Morrison J (2006). A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 163:2072-2079.
40. Lambert TJ, Castle DJ (2003). Pharmacological approaches to the management of schizophrenia. Med J Aust 178:57-61.
41. Landry P, Dimitri É , Tessier S, Légaré N (2008). Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. J Clin Psychopharmacol 28:348-349.
42. Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC (2012). Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 135:113-122.
43. Lu M, Lane H, Chen K, Jann MW, Su M, Chang W (2000). Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 61:594-599.
44. Lu M, Lane H, Lin S, Chen K, Chang W (2004). Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 65:766-771.
45. Maayan L, Correll CU (2010). Management of antipsychotic-related weight gain. Expert Rev Neurother 10:1175-1200.
46. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19-32.
47. Narula PK, Rehan H, Unni K, Gupta N (2010). Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 118:218-223.
48. Newcomer JW (2007). Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68:8-13.
49. Obach RS, Ryder TF (2010). Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos 38:1381-1391.
50. Oh K, Park J, Lee SY, Hwang I, Kim JB, Park T, et al. (2011). Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism. Am J Physiol Endocrinol Metab 300:E624-E632.
51. Ojala K, Repo-Tiihonen E, Tiihonen J, Niskanen L (2008). Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. J Psychopharmacol 22:33-38.
52. Olesen OV, Linnet K (2000). Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 20:35-42.
53. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS (2009). Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 119:3078-3084.
54. Pfizer Canada Inc (2012). Pr-LIPITORs(Atorvastatin Calcium Tablets) Product Monograph. Kirkland, Canada: Pfizer Canada Inc.
55. Procyshyn RM, Wasan KM, Thornton AE, Barr AM, Chen EY, Pomarol-Clotet E, et al. (2007). Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci 32:331-338.
56. Procyshyn RM, Honer WG, Wu T, Ko R, McIsaac SA, Young AH, et al. (2010). Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 71:566-573.
57. Rabkin SW, Huff MW, Newman C, Sim D, Carruthers SG (1994). Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study. Hypertension 24:241-248.
58. Raedler TJ (2010). Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 23:574-581.
59. Ridker PM, Danielson E, Fonseca F, Genest J, Gotto AM Jr, Kastelein J, et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med 359:2195-2207.
60. Sattar N, Preiss D, Murray HM,Welsh P, Buckley BM, de Craen AJ, et al. (2010). Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735-742.
61. Stahl S, Mignon L, Meyer J (2009). Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 119:171-179.
62. Su J, Barr AM, Procyshyn RM (2012). Adverse events associated with switching antipsychotics. J Psychiatry Neurosci 37:E1-E2.
63. Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A, et al. (2005). Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 96:243-251.
64. US FDA (2012). FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs.
65. US Food and Drug Administration (2008). Rozerem (ramelteon) Tablets October 2008: Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER)-October 2008. Silver Spring, USA: Food and Drug Administration, US Department of Health and Human Services.
66. Woo YS, Kim W, Chae J, Yoon B, Bahk W (2009). Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients. World J Biol Psychiatry 10:420-425.
67. Wu R, Zhao J, Jin H, Shao P, Fang M, Guo X, et al. (2008). Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain. JAMA 299:185-193.
68. Yamashita H, Yoda H, Kuroki N, Kuwabara M, Odagaki Y, Kazawa T, et al. (2011). Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine. Psychopharmacology (Berl) 213:1-9. Canada